Astellas doesn’t buy Apellis
In purchasing Iveric for $5.9bn the Japanese group has plumped for the cheaper geographic atrophy player.
Viridian aims to prove itself in thyroid eye
Forthcoming data will see the group take on Horizon, but subcutaneous projects could pose the real threat.
Go or no go? Overcoming delays
US Pdufa decisions loom for Apellis and Travere, while Menarini and Lilly got their approval firsts already.
Amgen strikes out for the Horizon
Amgen sees off Sanofi and J&J to clinch the rare disease player for $28bn, ensuring that the M&A year ends with a bang.
Makeover sees Viatris move further away from generics
The speciality group will soon be without biosimilars; in the meantime it's buying two companies with patent-protected medicines.
